The Fanconi Anemia drugs in development market research report provides comprehensive information on the therapeutics under development for Fanconi Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Fanconi Anemia. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Fanconi Anemia and features dormant and discontinued products.

GlobalData tracks 15 drugs in development for Fanconi Anemia by 13 companies/universities/institutes. The top development phase for Fanconi Anemia is phase ii with eight drugs in that stage. The Fanconi Anemia pipeline has ten drugs in development by companies and five by universities/ institutes. Some of the companies in the Fanconi Anemia pipeline products market are: Rocket Pharmaceuticals, Novartis and Centers of Biomedical Research Network.

The key targets in the Fanconi Anemia pipeline products market include Fanconi Anemia Group A Protein (Protein FACA or FANCA), Fanconi Anemia Group C (Protein FACC or FANCC), and Fanconi Anemia Group G Protein (DNA Repair Protein XRCC9 or FANCG).

The key mechanisms of action in the Fanconi Anemia pipeline product include Fanconi Anemia Group A Protein (Protein FACA or FANCA) Activator with five drugs in Phase II. The Fanconi Anemia pipeline products include four routes of administration with the top ROA being Intravenous and four key molecule types in the Fanconi Anemia pipeline products market including Gene-Modified Cell Therapy, and Small Molecule.

Fanconi Anemia overview

Fanconi anemia, or FA, is a rare, inherited blood disorder that leads to bone marrow failure. FA is a type of aplastic anemia. In aplastic anemia, the bone marrow stops making or doesn’t make enough of all three types of blood cells. Low levels of the three types of blood cells can harm many of the body’s organs, tissues, and systems. Treatment is recommended for significant cytopenias, such as hemoglobin less than 8g/dL or platelets fewer than 500/μL.

For a complete picture of Fanconi Anemia’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.